Loading
Jiangsu Aidea Pharmaceutical Group Co., Ltd. Stock: price and insider trades · China
艾迪药业
1 insider bought €392k of shares over the last 90 days, the latest by 傅和亮, filed 31 Jul 2026.
Jiangsu Aidea Pharmaceutical Group Co., Ltd.: what insiders have been doing
Jiangsu Aidea Pharmaceutical Group Co., Ltd., classified in the Health Care sector, is a listed company. Its insiders report their share dealings to SSE / SZSE (CSRC). Over the twelve months to 24 October 2026, 6 filings were filed, from 1 insider.
Not one open-market sale was filed. On the buying side, 1 insider reported 6 purchases totalling €1.1M. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. On the buying side, the filings list 1 board member among the declarants. Biggest ticket of the year: €280k, bought by 傅和亮 and made public on 4 March 2026.
With 6 filings in twelve months, the company is more active than the median of 2 filings across the 515 companies we follow on the same exchange. Since 2022, the database holds 13 purchases and 1 sale by insiders of the company.
The clock since the last published purchase (31 July 2026) now reads 85 days. Half of the filings or more reach the SSE / SZSE (CSRC) feed on the day of the trade. The shorter that gap, the sooner other investors can see what insiders have done.
Other companies in the same sector with recent insider buying flagged by our signals: MAIA Biotechnology, Inc. and Cooper Companies, Inc. These figures are compiled from regulatory filings published by SSE / SZSE (CSRC). They describe what insiders did and are not a recommendation.
Insider Decl.
14
Thresholds
n/a
Buy Volume
€2M
13 ops. · all time
Sell Volume
€121,577
1 ops. · all time
Who traded when
BuySale傅和亮6 buys
Since the insiders bought
- +5.8%Entry CN¥13.19 · Close 14 Oct 2026 CN¥13.95
- -38.7%Entry CN¥10.88 · Close at T+365 CN¥6.67
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 19,303 of 26,250 companies
35.5
score / 100
Value33
Quality38
FCF yld-0.5%
Earn yld-0.3%
EV/EBITDA·
ROE1.3%
Gross mgn67%
Net mgn-2.7%
Debt/EBITDA5.8x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
CN¥13.95
Analyst consensus
Income statement
RevenueCN¥719.2M
Gross profitCN¥480.4M67% margin
EBITDACN¥95.8M13% margin
Net income-CN¥19.5M-0.8% margin
Valuation
P/Book6.4x
Beta0.48
Balance sheet & cash
Market capCN¥5.9B
Total debtCN¥559.2M
Free Cash Flow-CN¥30.3M
Debt / Equity77%
Profitability & ownership
ROE1.3%
ROA1.7%
% insiders49.8%
% institutions12.3%
Last declaration on 31 July 2026
Declarations14 total
70,610 shares@ CN¥109.87495.3% of flowA股XSHGSSE:273000000973490430
Canonical exit: 29 Oct 2026 (T+90)
132,800 shares@ CN¥118.323210.8% of flowA股XSHGSSE:273000000894431740
Canonical exit: 25 Oct 2026 (T+90)
77,893 shares@ CN¥114.03285.9% of flowA股XSHGSSE:273000000679839650
Canonical exit: 31 Aug 2026 (T+90)
68,800 shares5.8% of flowA股XSHGSSE:273000000236276600
Canonical exit: 7 Jun 2026 (T+90)
53,079 shares4.5% of flowA股XSHGSSE:273000000231957980
Canonical exit: 3 Jun 2026 (T+90)
133,070 shares11.5% of flowA股XSHGSSE:273000000227204130
Canonical exit: 2 Jun 2026 (T+90)
107,718 shares66.1% of flowA股XSHGSSE:173000008167046720
100,000 shares5.1% of flowA股XSHGSSE:173000007827567680
Canonical exit: 7 Oct 2024 (T+90)
146,400 shares7.0% of flowA股XSHGSSE:173000007815776060
Canonical exit: 2 Oct 2024 (T+90)
200,000 shares13.5% of flowA股XSHGSSE:173000007270051780
Canonical exit: 21 Apr 2024 (T+90)
200,000 shares14.0% of flowA股XSHGSSE:173000007054153300
Canonical exit: 30 Jan 2024 (T+90)
189,700 shares13.5% of flowA股XSHGSSE:173000007054153250
Canonical exit: 29 Jan 2024 (T+90)
68,319 shares33.9% of flowA股XSHGSSE:173000006953582370
Canonical exit: 19 Dec 2023 (T+90)
61,000 shares3.1% of flowA股XSHGSSE:173000005549941020
Canonical exit: 23 Aug 2022 (T+90)
14 of 14 declarations
About Jiangsu Aidea Pharmaceutical Group Co., Ltd.
艾迪药业 is a company in the health and pharmaceutical sector, listed on the Shanghai Stock Exchange. It focuses on the development and commercialization of innovative pharmaceutical products.
